Lynparza Maintenance Reduces Risk of Disease Progression in Advanced Ovarian Cancer Patients, SOLO-2 Trial Shows
News
Women with BRCA-mutated relapsed ovarian cancer whose tumors responded to platinum-based chemotherapy took significantly longer to see their disease progressing when given AstraZeneca’s Lynparza (olaparib) as a maintenance therapy, compared to placebo. In addition to ... Read more